trail 1
hits 1
acquisition 1
Novartis 1
trail 1
hits 1
acquisition 1
Novartis 1
Novartis 2
£3.9bn) 1
world's 1
unit 1
trail 1
to 1
the 1
purchases 1
producer. 1
of 1
make 1
its 1
hits 1
has 1
generic 1
euros 1
drugmaker 1
drug 1
biggest 1
announced 1
acquisition 1
Swiss 1
Sandoz 1
5.65bn 1
($7.4bn; 1
Novartis 2
£3.9bn) 1
world's 1
unit 1
trail 1
to 1
the 1
purchases 1
producer. 1
of 1
make 1
its 1
hits 1
has 1
generic 1
euros 1
drugmaker 1
drug 1
biggest 1
announced 1
acquisition 1
Swiss 1
Sandoz 1
5.65bn 1
($7.4bn; 1
to 4
of 4
the 3
Novartis 3
shares 2
said 2
make 2
it 2
for 2
Swiss 2
£3.9bn) 1
year 1
would 1
world's 1
which 1
unit 1
trail 1
trading. 1
that 1
savings 1
sales 1
rose 1
remaining 1
record 1
purchases 1
producer. 1
offered 1
month 1
last 1
its 1
in 1
hits 1
has 1
had 1
generic 1
francs 1
forecast 1
following 1
euros 1
early 1
each. 1
drugmaker 1
drug 1
cost 1
buy 1
bought 1
biggest 1
be 1
announced 1
and 1
also 1
all 1
affiliate 1
acquisitions. 1
acquisition 1
acquired 1
about 1
able 1
a 1
US 1
Sandoz 1
Novartis, 1
Novartis' 1
Labs, 1
It 1
Hexal. 1
Hexal's 1
Germany's 1
Eon 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
1% 1
($7.4bn; 1
$31 1
$200m 1
to 4
of 4
the 3
Novartis 3
shares 2
said 2
make 2
it 2
for 2
Swiss 2
£3.9bn) 1
year 1
would 1
world's 1
which 1
unit 1
trail 1
trading. 1
that 1
savings 1
sales 1
rose 1
remaining 1
record 1
purchases 1
producer. 1
offered 1
month 1
last 1
its 1
in 1
hits 1
has 1
had 1
generic 1
francs 1
forecast 1
following 1
euros 1
early 1
each. 1
drugmaker 1
drug 1
cost 1
buy 1
bought 1
biggest 1
be 1
announced 1
and 1
also 1
all 1
affiliate 1
acquisitions. 1
acquisition 1
acquired 1
about 1
able 1
a 1
US 1
Sandoz 1
Novartis, 1
Novartis' 1
Labs, 1
It 1
Hexal. 1
Hexal's 1
Germany's 1
Eon 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
1% 1
($7.4bn; 1
$31 1
$200m 1
of 7
the 6
to 4
Novartis 4
would 3
that 3
said 3
it 3
world's 2
shares 2
sales 2
make 2
for 2
biggest 2
be 2
a 2
Swiss 2
Sandoz 2
Novartis' 2
£3.9bn) 1
year 1
will 1
which 1
unit 1
trail 1
trading. 1
there 1
than 1
see 1
savings 1
rose 1
remaining 1
record 1
purchases 1
producer. 1
producer 1
overtake 1
on 1
offered 1
number 1
newly 1
more 1
month 1
merged 1
merge 1
may 1
maker 1
last 1
job 1
its 1
in 1
hits 1
have 1
has 1
had 1
generics. 1
generic 1
francs 1
forecast 1
following 1
figures 1
euros 1
estimated. 1
early 1
each. 1
drugmaker 1
drug 1
departments, 1
deal 1
cuts. 1
cost 1
company 1
buy 1
business 1
bought 1
as 1
announced 1
and 1
also 1
all 1
affiliate 1
adding 1
acquisitions. 1
acquisition 1
acquired 1
about 1
able 1
US 1
The 1
Teva 1
Pharmaceuticals 1
Novartis, 1
Labs, 1
It 1
Israel's 1
Hexal. 1
Hexal's 1
Germany's 1
Eon 1
Based 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
2004 1
1% 1
($7.4bn; 1
$5bn, 1
$31 1
$200m 1
of 7
the 6
to 4
Novartis 4
would 3
that 3
said 3
it 3
world's 2
shares 2
sales 2
make 2
for 2
biggest 2
be 2
a 2
Swiss 2
Sandoz 2
Novartis' 2
£3.9bn) 1
year 1
will 1
which 1
unit 1
trail 1
trading. 1
there 1
than 1
see 1
savings 1
rose 1
remaining 1
record 1
purchases 1
producer. 1
producer 1
overtake 1
on 1
offered 1
number 1
newly 1
more 1
month 1
merged 1
merge 1
may 1
maker 1
last 1
job 1
its 1
in 1
hits 1
have 1
has 1
had 1
generics. 1
generic 1
francs 1
forecast 1
following 1
figures 1
euros 1
estimated. 1
early 1
each. 1
drugmaker 1
drug 1
departments, 1
deal 1
cuts. 1
cost 1
company 1
buy 1
business 1
bought 1
as 1
announced 1
and 1
also 1
all 1
affiliate 1
adding 1
acquisitions. 1
acquisition 1
acquired 1
about 1
able 1
US 1
The 1
Teva 1
Pharmaceuticals 1
Novartis, 1
Labs, 1
It 1
Israel's 1
Hexal. 1
Hexal's 1
Germany's 1
Eon 1
Based 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
2004 1
1% 1
($7.4bn; 1
$5bn, 1
$31 1
$200m 1
the 9
to 7
of 7
said 4
for 4
Novartis 4
would 3
that 3
more 3
it 3
in 3
as 3
and 3
a 3
Sandoz 3
world's 2
will 2
which 2
their 2
shares 2
sales 2
make 2
have 2
can 2
branded 2
biggest 2
be 2
Swiss 2
Novartis' 2
£3.9bn) 1
year 1
work 1
usually 1
unit 1
trail 1
trading. 1
they 1
there 1
them 1
than 1
such 1
strong 1
statement. 1
sell 1
see 1
savings 1
rose 1
rivals. 1
research 1
remaining 1
reductions 1
record 1
purchases 1
protection 1
products 1
producer. 1
producer 1
pay 1
patent 1
partially 1
overtake 1
outlook 1
on 1
offered 1
number 1
not 1
newly 1
necessary 1
month 1
merged 1
merge 1
may 1
maker 1
last 1
jobs, 1
job 1
its 1
is 1
identical 1
hits 1
has 1
had 1
growth 1
generics. 1
generic 1
francs 1
forecast 1
force," 1
following 1
firm 1
figures 1
expires 1
expensive 1
expected 1
euros 1
estimated. 1
early 1
each. 1
drugs 1
drugmaker 1
drug 1
do 1
development 1
departments, 1
deal 1
cuts. 1
create 1
cost. 1
cost 1
copy 1
compensate 1
company 1
chemically 1
cheaply 1
buy 1
business 1
bought 1
are 1
announced 1
also 1
all 1
after 1
affiliate 1
adding 1
acquisitions. 1
acquisition 1
acquired 1
about 1
able 1
US 1
The 1
Teva 1
Sandoz, 1
Producers 1
Pharmaceuticals 1
Novartis, 1
Labs, 1
It 1
Israel's 1
Hexal. 1
Hexal's 1
Germany's 1
Generic 1
Eon 1
Based 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
2004 1
1% 1
($7.4bn; 1
$5bn, 1
$31 1
$200m 1
"The 1
the 9
to 7
of 7
said 4
for 4
Novartis 4
would 3
that 3
more 3
it 3
in 3
as 3
and 3
a 3
Sandoz 3
world's 2
will 2
which 2
their 2
shares 2
sales 2
make 2
have 2
can 2
branded 2
biggest 2
be 2
Swiss 2
Novartis' 2
£3.9bn) 1
year 1
work 1
usually 1
unit 1
trail 1
trading. 1
they 1
there 1
them 1
than 1
such 1
strong 1
statement. 1
sell 1
see 1
savings 1
rose 1
rivals. 1
research 1
remaining 1
reductions 1
record 1
purchases 1
protection 1
products 1
producer. 1
producer 1
pay 1
patent 1
partially 1
overtake 1
outlook 1
on 1
offered 1
number 1
not 1
newly 1
necessary 1
month 1
merged 1
merge 1
may 1
maker 1
last 1
jobs, 1
job 1
its 1
is 1
identical 1
hits 1
has 1
had 1
growth 1
generics. 1
generic 1
francs 1
forecast 1
force," 1
following 1
firm 1
figures 1
expires 1
expensive 1
expected 1
euros 1
estimated. 1
early 1
each. 1
drugs 1
drugmaker 1
drug 1
do 1
development 1
departments, 1
deal 1
cuts. 1
create 1
cost. 1
cost 1
copy 1
compensate 1
company 1
chemically 1
cheaply 1
buy 1
business 1
bought 1
are 1
announced 1
also 1
all 1
after 1
affiliate 1
adding 1
acquisitions. 1
acquisition 1
acquired 1
about 1
able 1
US 1
The 1
Teva 1
Sandoz, 1
Producers 1
Pharmaceuticals 1
Novartis, 1
Labs, 1
It 1
Israel's 1
Hexal. 1
Hexal's 1
Germany's 1
Generic 1
Eon 1
Based 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
2004 1
1% 1
($7.4bn; 1
$5bn, 1
$31 1
$200m 1
"The 1
the 10
to 7
of 7
that 5
in 5
a 5
they 4
said 4
more 4
it 4
for 4
and 4
Novartis 4
would 3
have 3
as 3
are 3
Sandoz 3
world's 2
will 2
which 2
their 2
than 2
shares 2
sales 2
not 2
make 2
is 2
generic 2
expensive 2
can 2
branded 2
biggest 2
be 2
analysts 2
all 2
about 2
Swiss 2
Novartis' 2
£3.9bn) 1
year 1
worldwide 1
work 1
where 1
were 1
very 1
usually 1
unit 1
trail 1
trading. 1
told 1
those 1
there 1
them 1
suffered 1
such 1
strong 1
strange 1
statement. 1
sell 1
see 1
savings 1
rose 1
rivals. 1
research 1
remaining 1
reductions 1
record 1
purchases 1
protection 1
products 1
producer. 1
producer 1
price 1
pressure." 1
predicted 1
pay 1
patent 1
partially 1
overtake 1
outlook 1
on 1
offered 1
number 1
newly 1
necessary 1
month 1
merged 1
merge 1
may 1
markets 1
market 1
making 1
maker 1
last 1
jobs, 1
job 1
its 1
investment 1
initially 1
identical 1
hits 1
has 1
had 1
growth 1
generics. 1
from 1
francs 1
fragmented. 1
forecast 1
force," 1
following 1
firm 1
find 1
figures 1
expires 1
expected 1
exactly 1
euros 1
estimated. 1
early 1
each. 1
drugs 1
drugmakers 1
drugmaker 1
drug 1
do 1
development 1
departments, 1
deal. 1
deal 1
cuts. 1
create 1
cost. 1
cost 1
copy 1
convinced 1
consolidation 1
compensate 1
company 1
chemically 1
cheaply 1
call 1
buy 1
business 1
bought 1
bank, 1
announced 1
also 1
after 1
affiliate 1
adding 1
acquisitions. 1
acquisitions 1
acquisition," 1
acquisition 1
acquired 1
able 1
US 1
There 1
The 1
Teva 1
Sandoz, 1
Sal 1
Reuters. 1
Producers 1
Pharmaceuticals 1
Oppenheim 1
Novartis, 1
Labs, 1
Kuhlhoff, 1
It 1
Israel's 1
However, 1
Hexal. 1
Hexal's 1
Germany's 1
Generic 1
Eon 1
Birgit 1
Based 1
67.7% 1
57.85 1
5.65bn 1
2005, 1
2004 1
150 1
1% 1
($7.4bn; 1
$5bn, 1
$31 1
$200m 1
"This 1
"The 1
"I 1
